ABSTRACT Traditionally, antibiotic growth promoters (AGP) have been used in foodstock animals to reduce enteric inflammation and maintain intestinal homeostasis, thus improving growth and performance. Due to increasing restrictions regarding the use of AGP however, precise and high throughput enteric inflammation models and markers to search for effective alternatives are urgently needed. In this paper, oral administration of fluorescein isothiocyanate dextran (FITCd, 3-5 kDa) and its passage into blood was used as a marker for tight junction permeability. In experiement 1, broilers were assigned to a control group, a group which received 24 h feed restriction (FR), or a group which received dextran sodium sulfate (DSS) (0.75% in water for 5 d), and each group then underwent an oral gavage of FITC-d 2.5 h before sample collection on d10. FITC-d in serum and intestinal samples (duodenum and ceca) were found to be higher (P < 0.05) after FR than in the DSS and control groups. In experiment 2, FR was evaluated for its effect on mucosal leakage and an oral dose of FITC-d of 0.5, 1.1, or 2.2 mg/chick was used to measure the gastrointestinal tract (GIT) permeability at 6 d of age. The amount of FITC-d remaining in the duodenal tissue of the control birds increased with dose, only the 1.1 mg FITCd/chick dose resulted in differences (P < 0.05) between the control and FR groups. No differences were noted between the control and FR groups, regardless of FITCd dosage in cecal recovery of FITC-d. Additionally, FR increased FITC-d serum levels when compared to the control group and in a dose-dependent manner. Experiment 3 compared serum levels after administration of 0.55 and 1.1 mg/chick doses of FITC-d in birds treated with FR, rye-based diet (RBD), and DSS. Intestinal sections were collected for FITC-d recovery in the 1.1 mg dosage group. All inflammation treatments significantly increased serum FITC-d levels at both doses. Only FR resulted in increased (P < 0.05) FITC-d recovery from duodenum, ileum, and ceca. In conclusion, FR, DSS, and RBD affected GIT tight junction integrity, suggesting their value for enteric inflammation models, and FITC-d may be a good indicator of permeability.
INTRODUCTION
The GIT has numerous physiological functions including effective absorption of dietary nutrients and plays a key role as a barrier against enteric pathogens, thus integrity and repair are vital for protection of animals against disease and optimal production performance. The mucous layer, tight junctions between epithelial cells, and gut-associated lymphoid tissue help to maintain a homeostasis between dietary antigens, in addition to enteric pathogens and beneficial microorganisms (Van Der Hulst et al., 1998) . Disruption of gut health and its barrier results in nonselective permeability and could lead to malabsorption of nutrients and translocation of a greater amount of enteric bacteria to various internal organs which may lead to diseases and reduced growth performance (Quinteiro-Filho et al., 2012) . Furthermore, increasing grain prices, concerns over subtherapeutic antibiotic feed additives antibiotic growth promoters (AGP) and diminished animal well-being have driven a need for new sustainable disease management practices and improved feed efficiency for the poultry industry.
Although the mechanism by which subtherapeutic AGP result in modulations of microbial presence, the beneficial performance effects of inclusion of AGP are clear (Butaye et al., 2003) . Possible mechanisms by which AGP modulate gut microflora include suppression of bacterial pathogens, reduction of nutrient use, increased production of vitamins and other nutrients, and reduced production of ammonia (Butaye et al., 2003) . Additionally, AGP have a profound impact on growth rate and feed efficiency, possibly through effects on stabilization of the microbial populations (Gunal et al., 2006) . Importantly, AGP are known to reduce intestinal disease frequency and severity, reduce mortality, while reducing feed usage and improving rate of gain in monogastric animals, including poultry (Dibner and Richards, 2005) .
In the case of poultry, it has been proposed that one benefit of antibiotic growth promoters is functional control of enteric inflammation, (Niewold, 2007) . Niewold (2007) also pointed out that many popular AGP are classes that accumulate in phagocytes with known attenuation of the innate inflammatory response. This hypothesis is consistent with the observation that the intestinal walls of AGP-fed animals are thinner than non-AGP treated chickens (Jukes et al., 1956 ), which could be attributed to a reduced influx of inflammatory cells although the authors did not test this hypothesis. They did, however, note that duodenal lamina propria thickness was reduced. Models of enteric inflammation are not currently well-developed in poultry, which hinders the search for a complete understanding of the roll of AGP in production, as well as the development of alternative additives that could provide the same, or better, functions. Thus, there is an urgent need to develop enteric inflammation and permeability models in poultry that can both aid in elucidating the performanceenhancing effects of AGP, and in the search for alternatives.
Recent publications describing rodent models of enteric inflammation and leaky gut have described FITC-d as a marker of enteric leakage (Shah et al., 2007; Brandl et al., 2009; Yan et al., 2009) . Yan et al. (2009) demonstrated an increase in paracellular leakage associated with DSS treatment by measuring the serum levels of FITC-d 4 h after FITC-d oral gavage. Similarly, starvation in mice resulted in reduced gut epithelial cell proliferation and increased apoptosis (Chappell et al., 2003) . These findings suggest that induction of gut inflammation and measurement of gut leakage using FITC-d could be an effective method to study gut health.
The studies herein were designed to evaluate multiple inducers of enteric inflammation and dosages of FITCd as a marker of leaky gut. Feed restriction (FR) is a common practice for breeder stock because genetic selection for growth parameters in meat type chickens gives rise to a parent stock (broiler breeders) that tends to possess high body mass associated with excessive fat deposition, lameness, and high mortality rates often due to skeletal and/or cardiovascular disease. In order to regulate weight gain, limit health risks, and also maintain high fertility, husbandry practices for the parent stock of broiler chickens include a high degree of FR (Lee et al., 1971; Yu et al., 1992) . Well-being and disease susceptibility during FR are a concern for producers, thus FR was evaluated for its impact on enteric permeability. Additionally, alternative feedstuffs such as wheat and rye are not uncommon, and often contain high levels of non-starch polysaccharides (Choct et al., 1995) . Such diets often lead to higher susceptibility to necrotic enteritis and increased digesta viscosity (Annett et al., 2002; Tellez et al., 2014) . The purpose of the present studies was to evaluate alterations in gut permeability under inflammation and stress induced by FR, high non-starch polysaccharides diet, or DSS, which are previously studied inducers of leaky gut in broilers (Kuttappan et al., 2014a, b; Latorre et al., 2014; Menconi et al., 2014; Tellez et al., 2014) . Additionally, multiple doses of FITC-d were evaluated for serum and intestinal recovery to help optimize optimal detection of gastrointestinal permeability as a marker of enteric inflammation.
MATERIAL AND METHODS

Experimental Animals
Day of hatch broiler chicks were obtained from a primary breeder and randomly assigned to treatment groups. Chicks were housed in brooder battery cages with wire floors. Throughout each experiment, chicks were provided a diet that met or exceeded NRC requirements (National Research Council, 1994) , except the FR groups, and were provided with water ad libitum throughout the research period. A previously determined dose for drinking water administration of DSS (MW 40,000; Alfa Aesar, Ward Hill, MA) was provided as a 0.75% solution ad libitum as described below in experimental design (Menconi et al., 2014) . The rye-based diet (RBD) was formulated as previously described as an inducer of leaky gut, and both control and rye-based diet are described in Table 1 . Ryebased diet was provided as the sole source of nutrition during d5-d7 in experiment 3, described below.
To detect enteric leakage, chickens were dosed with FITC-d (MW 3,000-5,000; Sigma Aldrich Co., St. Louis, MO) by oral gavage at concentrations described below. Previous unpublished data from our laboratory have suggested that 2.5 h after oral gavage with FITCd is the optimal time for blood collection from broilers. Birds were killed by CO 2 inhalation, and blood and intestinal tissue samples were collected post-mortem. All animal handling procedures were in compliance with Institutional Animal Care and Use Committee regulation at the University of Arkansas.
FITC-d Fluorescence in Blood
For detection of FITC-d in serum, blood was kept at room temperature for 3 h to allow clotting, and centrifuged (500×g for 15 min) to separate serum. Fluorescence levels of diluted serum (1:1 in PBS) were measured at an excitation wavelength of 485 nm and emission wavelength of 528 nm (Synergy HT, Multi-mode 1 Vitamin premix supplied the following per kg: vitamin A, 20,000,000 IU; vitamin D3, 6,000,000 IU; vitamin E, 75,000 IU; vitamin K3, 9 g; thiamine, 3 g; riboflavin, 8 g; pantothenic acid, 18 g; niacin, 60 g; pyridoxine, 5 g; folic acid, 2 g; biotin, 0.2 g; cyanocobalamin, 16 mg; and ascorbic acid, 200 g (Nutra Blend LLC, Neosho, MO 64850).
2 Mineral premix supplied the following per kg: manganese, 120 g; zinc, 100 g; iron, 120 g; copper, 10-15 g; iodine, 0.7 g; selenium, 0.4 g; and cobalt, 0.2 g (Nutra Blend LLC, Neosho, MO 64850).
3 Ethoxyquin.
microplate reader, BioTek Instruments, Inc., VT), and FITC-d concentration per mL of serum was calculated based on a standard curve.
Tissue Levels of FITC-d
Measurement of FITC-d released from intestinal tissue was accomplished by collection of 2.5 cm sections of GIT which were cleaned by flushing with Hanks buffered salt solution, weighed and placed in tubes with 10 mL of Hanks buffer containing glutamine (0.3 g/L) and antimicrobial agents (Penicillin 100 μ/mL; Streptomycin 0.01 mg/mL; Amphotericin B 0.25 μg/mL). Duodenal samples were collected from the descending duodenum, ileal samples from immediately proximal to the Meckel's diverticulum, and a single entire cecum for tissue sampling. The tubes were incubated for 2 h at 42
• C and sampled by collecting 100 μL of buffer from each tube. Levels of FITC-d in the buffer in the tubes were determined by fluorescence measurement as described above for serum, with the final concentration reported as μg/g of ileal tissue.
Experimental Design Experiment 1. Evaluation of Feed Restriction and
Dextran Sodium Sulfate on Enteric Leakage. Thirty chicks were comingled in a single wire-floor brooder battery cage for 10 d, at which point they were randomly separated into three separate cages according to treatment group (n = 10/group) -control (CON), FR, or DSS for the remainder of the experiment. At 10 d, the DSS group began receiving 0.75% DSS in drinking water, and continued treatment through the end of the experiment. At 13 d FR began and continued for 24 h through the end of the experiment. Fluorescein isothiocyanate-dextran (2.2 mg/bird) for serum detection was administered by oral gavage at 14 d.
Experiment 2. Evaluation of Three Doses of FITCd in Serum and GIT Tissue After Feed Restriction. Forty-eight-day-old hatch chicks were randomly separated into wire-floor brooder battery cages (24 chicks/cage) and reared with feed and water ad libitum for 5 d. At 6 d feed was removed from one group, FR, for the remainder of the experiment (24 h). Concentrations of FITC-d at 0.55 mg/chick, 1.1 mg/chick, or 2.2 mg/chick were administered by oral gavage to 8 chicks each in CON and FR groups at 7 d. Blood, duodenum, and ceca were collected 2.5 h after administration of FITC-d. 
Statistical Analysis
Data were analyzed using ANOVA (SAS 9.3, SAS Institute Inc., Cary, NC), and means were separated with Duncan's significant difference test with P < 0.05 considered as significant. Individual birds were considered as the experimental unit for the entire analysis. In all trials, data are expressed as mean ± SE.
Data from serum FITC-d levels were analyzed in 2 × 2 factorial (treatment X dose) using JMP Pro 11.2.0 (SAS Institute Inc., Cary, NC) and the main effects of treatment, dose, and interaction between treatment and dose were evaluated. Serum FITC-d data showed occasional, but random, high values which were not representative of the respective group means. Although the reason/s for such high FITC-d values is/are still not clear, it does not seem to be related to treatment. Since these values were creating noise in the analysis, outliers from treatment groups were identified as above or below two standard deviations from mean, based on empirical or 68-95-99.7 rule. Identified outliers were trimmed, or truncated, according to (Ghosh and Vogt, 2012) . Analysis of experiments 2 and 3 serum (0.55 and 1.1 mg/chick doses) from CON and FR were completed both with unedited and truncated data, and results are reported as mean ± SE and P values for the respective main effects to describe this phenomenon. Main effects with P-value less than 0.05 were considered significant. All other reported data for serum and tissue samples represent truncated values, with the number of outliers removed reported.
RESULTS
Serum FITC-d
Various inducers of leaky gut were compared for ability to increase FITC-d passage into serum, including FR, DSS, and RBD. In experiment 1, both FR and DSS, with recovery levels of 0.364 ± 0.017 and 0.279 ± 0.01 μg/mL respectively, resulted in higher (P < 0.05) levels of FITC-d (2.2 mg/bird) than the control chicks at 0.182 ± 0.015 μg/mL (Table 2 ). Feed restriction also caused higher (P < 0.05) levels of serum FITC-d than the controls, at 0.218 ± 0.007 vs. 0.131 ± 0.02 μg/mL, in experiment 2 when administered at 0.55 mg/bird, but not at other doses. Additionally, all three tested enteric inflammation treatments; FR, RBD, and DSS, showed significantly increased FITC-d recovery compared to control serum, regardless of the FITC-d dose in experiment 3.
Furthermore, multiple doses of FITC-d were tested to determine the optimal concentration for measuring enteric leakage. In experiment 2, three doses, 0.55 mg/bird, 1.1 mg/bird, and 2.2 mg/bird were evaluated after 24 h FR, with 0.55 mg FITC-d/bird being the only dose that resulted in a significant difference from the controls with recovery levels at 0.218 ± 0.007 μg/mL in FR group and 0.131 ± 0.02 μg/mL in the control group (Table 2) . It was also noted that as FITCd dosage increased, the level of recovery from control serum also rose in a dose-dependent manner of 0.131 ± 0.014, 0.201 ± 0.035, and 0.302 ± 0.032 μg/mL of serum for 0.55, 1.1, and 2.2 mg FITC-d/bird, respectively. Also, the difference between control and FR groups became less apparent as the amount of FITC-d increased ( Figure 1B) . While 0.55 mg/bird dose of FITC-d also resulted in significant differences from the control group in experiment 3, 1.1 mg/bird dose of FITC-d resulted in the greatest difference from the control group for FR, RBD, and DSS (Table 2) .
Tissue FITC-d
Experiments 2 and 3 evaluated tissue recovery of FITC-d by oral gavage to help determine which regions of GIT are affected by each method of induction. Three doses of FITC-d, 0.55, 1.1, and 2.2 mg/bird, were tested for recovery in duodenum and cecum in experiment 2. Only the dosage of 1.1 mg/bird of FITC-d results in a significant (P < 0.05) difference from the control group after 24 h FR, with 1.245 ± 0.071 μg/g and 1.709 ± 0.176 μ/g of tissue in control and FR groups, respectively (Table 4) . No differences were measured between control and FR groups in cecal levels of FITC-d. In contrast, FR increased recovery of FITC-d from all three GIT tissues in experiment 3, in which only 1.1 mg/bird FITC-d was measured. Duodenum tissue recovery increased from 1.267 ± 0.217 μg/g in control birds to 3.057 ± 0.288 μg/g in FR birds, ileum recovery of FITC-d was 3.541 ± 0.664 μg/g for control group vs. 11.40 ± 3.099 μg/g in FR group, and cecal increased from 6.082 ± 0.916 μg/g in control birds to 15.071 ± 1.943 μg/g in FR birds. Both RBD and DSS failed to result in elevated FITC-d tissue recovery for all intestinal sections.
DISCUSSION
Increasing grain prices and concerns over subtherapeutic antibiotic feed additives and diminished animal well-being have driven a need for new sustainable disease management practices and improved feed efficiency for the poultry industry. In recent years, non-antibiotic feed additive and probiotic research has surged, but measuring the effect of these strategies has traditionally been limited to gross performance or pathological evaluation. The critical need for effective AGP alternatives was the focus of a 2012 OIE (The World Organization for Animal Health)/USDA conference where issues related to the increasing environmental footprint of monogastric animal agriculture, increased costs associated with production, and decreased animal well-being were clearly associated with the current and impending loss of these important drugs in many parts of the world (Seal et al., 2013) . The ongoing diminution of AGP usage is estimated to reduce feed efficiency of monogastric animals by approximately 6 to 10% (reviewed by (Thomke and Elwinger, 1998; Bedford, 2000) .
An emerging and compelling hypothesis as to the mechanism of AGP implicates reduced enteric inflammation as an underlying common modality for benefits associated with the addition of AGP (Niewold, 2007) . Intestinal imbalances, or dysbiosis, are the result of changes such as diet, infection, or even stressors that affect intestinal microflora. The resulting inflammation from these imbalances is thus associated with intestinal disease regardless of etiology (Lambert, 2009 ). While it is well-known that intestinal microflora are important potentiators of the intestinal host defenses, modulation of inflammatory responses is critical as common production problems related to inflammation are commonly related to an excessive, rather than insufficient, innate immune response (McCracken and Gaskins, 1999; Tracey, 2002) .
Thus measuring intestinal inflammation in the search for AGP replacements may be crucial to the selection process. Availability of such assay(s), specific for intestinal inflammation, is also expected to be useful for identifying both causes and preventatives for inflammation under a variety of nutritional programs and environmental conditions. Animal models for human GIT diseases, such as irritable bowel disorder, have been previously developed, and have well-established measurement protocols (Yan et al., 2009) . A common molecule for quantification of enteric inflammation is FITC-d, a molecule which does not usually leak through the intact gastrointestinal tract barrier (Rose et al., 2012) . However, when conditions disrupt tight junctions between epithelial cells, FITC-d can enter circulation, as demonstrated by an increase in trans-mucosal permeability associated with enteric inflammation treatment in these studies. Progressive detection of FITC-d in serum (Table 2 ) and gut tissue retention (Table 4) is consistent with leakage from the lumen and suggests the presence of a change in paracellular permeability rather than transcellular transport. Ex vivo evaluation of GIT permeability has been used as a method to determine gut leakage in animal models. For many of such studies, either an everted or non-everted intestinal section and a marker dye, like FITC-d or phenol red in buffer, and the rate of passage of dye across intestinal walls was used to estimate gut leakage (Nakamaru et al., 1997; Lambert, 2009; van der Meer et al., 2012) . Specially designed apparati, such as Ussing chambers, are required to perform some permeability assays are Table 3 . Effect of treatment (control or feed restriction, FR), dose of FITC-d (0.55 or 1.1 mg/chick), and interaction between treatment and dose on serum FITC-d (μg/mL) levels in experiments 2 and 3. FR was conducted 24 h immediately prior to oral gavage with FITC-d, blood samples were collected 2.5 h after dosage for detection. Serum FITCd levels reported as mean ± SE (μg/mL). slow, often lead to low number replications in experimental results (Dixit et al., 2012) , and are obviously devoid of circulatory, endocrine, and cytokine feedback mechanisms. The present studies suggest that decreased mucosal integrity can be measured in the simple FITCd assay as described.
Occasional outliers were noted in both serum and tissue FITC-d detection assays, and were presently reported with their inclusion or after removal from reported values when outliers were ± 2 standard deviations from the mean, as described by Ghosh and Vogt (2012;  Figure 1 and Table 3 ). These random extremely high values created noise in the data that made interpretation difficult, and although the cause of these outliers is not yet known, they do not seem related to FITC-d dose or treatment, as shown in Table 3 . Treatment X dose interaction was not significant for either truncated or unedited data in experiments 2 and 3, but removal of the outliers did occasionally change the Pvalue from P > 0.05 to P < 0.05, as shown in the experiment 2 treatment values. Furthermore, removal of two outliers from experiment 2 changed a dose response curve that was uninterpretable ( Figure 1A ) to one that followed expected results and can be interpreted do discern appropriate dosage for FITC-d detection of enteric leakage ( Figure 1B) . In fact, the curve presented in Figure 1B suggests that tested doses of FITC-d may be at the top of the dose-response curve, and further testing of lower concentrations may be warranted, because 0.55 mg/kg was the only concentration on the linear portion of the curve, and without truncation, this observation would not have been noted. While 1.1 mg/kg FITC-d was the only concentration tested that resulted in significant differences in tissue recovery (Table 4) , a lower dose of 0.55 mg/kg FITC-d appeared to more consistently result in a greater difference from the mean for serum samples (Table 2) . Feed restriction effects, as measured at 0.55, 1.1, and 2.2 mg/kg FITC-d, were 166%, 141%, and 128% greater than the respective control values for experiment 2, suggesting that background leakage decreases with FITC-d dose, a primary objective of these studies. Although regional enteric effects of the selected insults was not a primary goal of the present studies, tissue evaluation of regional enteric FITC-d provided some insight into relative inflammation of selected portions of the GIT.
These studies suggest that circulating levels of FITCd can be used for rapid evaluation of inflammatoryassociated enteric epithelial leakage, which may be useful in the search for AGP alternatives in future studies. Future evaluation and comparison of regional FITC-d recovery with specific enteric pathogen-induced enteric inflammatory insults may allow for determination of the value of FITC-d tissue retention following post-mortem sample collection, which may have value for diagnostic or other investigations related to idiopathic infectious etiologies.
